On the issue of cough treatment in COVID-19 patients
- 作者: Ovsyannikov E.S1, Feygelman S.N1, Alexeeva N.G1
-
隶属关系:
- Voronezh State Medical University named after N.N. Burdenko
- 期: 编号 4S (2022): Supplement
- 页面: 99-102
- 栏目: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/277102
- DOI: https://doi.org/10.18565/therapy.2022.4suppl.100-103
- ID: 277102
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Unproductive cough is one of the most frequent complaints in COVID-19, therefore, levodropropizine, a peripheral antitussive agent, was prescribed to 98 patients for its treatment (basic group). The comparison group consisted of 29 patients with COVID-19 with the same complaints who voluntarily refused to take the specified drug. As a result of the study, it was found that during 7 days of treatment with levodropropizine, the intensity and severity of dry cough during the day and at night significantly decreased.
全文:
作者简介
E. Ovsyannikov
Voronezh State Medical University named after N.N. Burdenko
S. Feygelman
Voronezh State Medical University named after N.N. Burdenko
N. Alexeeva
Voronezh State Medical University named after N.N. Burdenko
参考
- Paules C.I., Marston H.D., Fauci A.S. Coronavirus infections - more than just the common cold. JAMA. 2020; 323(8): 707-8. doi: 10.1001/jama.2020.0757.
- Dicpinigaitis P.V., Morice A.H., Birring S.S. et al. Antitussive drugs - past, present, and future. Pharmacol Rev. 2014; 66(2): 468-512. doi: 10.1124/pr.111.005116.
- Государственный реестр лекарственных средств Минздрава России. Инструкция по применению лекарственного препарата с МНН леводропропизин. Доступ: https://grls.rosminzdrav.ru (дата обращения - 25.04.2022).
- Орлова Н.В. Хронический кашель: дифференциальная диагностика и лечение. Медицинский совет. 2020; 17: 124-131. doi: 10.21518/2079-701X-2020-17-124-131.
补充文件
